A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exscientia PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 500 shares of EXAI stock, worth $2,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 1,200 58.33%
Holding current value
$2,345
Previous $6,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.26 - $6.0 $259,847 - $365,982
60,997 New
60,997 $297,000
Q2 2023

Aug 14, 2023

SELL
$4.79 - $8.3 $93,979 - $162,846
-19,620 Reduced 77.05%
5,845 $34,000
Q1 2023

May 15, 2023

SELL
$5.3 - $10.93 $490,297 - $1.01 Million
-92,509 Reduced 78.41%
25,465 $134,000
Q4 2022

Feb 14, 2023

BUY
$4.1 - $8.94 $483,693 - $1.05 Million
117,974 New
117,974 $628,000

Others Institutions Holding EXAI

About Exscientia plc


  • Ticker EXAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,461,000
  • Market Cap $574M
  • Description
  • Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...
More about EXAI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.